Buy Ranbaxy Labs; avoid OMCs stocks: Sukhani

Sudarshan Sukhani, s2analytics.com feels that one can buy Ranbaxy Laboratories and avoid OMCs stocks.

Sukhani told CNBC-TV18, “Ranbaxy Laboratories is now in its own bull market. It is outperforming and likely to outperform the Nifty. Ranbaxy remains a buying opportunity. Today after remaining in a consolidation it is moving up and at current levels can be bought into.”
He further added, “BPCL is part of the three oil marketing companies (OMCs) which are now to be avoided. Yesterday we had suggested selling HPCL and that broadly applies to all three of them so there is no buying here. I don’t think you should go short in this market so it is best to avoid them.”